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Background: Alterations to apoptosis are a common occurrence in human tumours. The aim of our study was to
determine the influence of apoptotic variations on the carcinogenesis and prognosis of colorectal carcinomas
(CRCs).
Methods: A TUNEL assay was performed on archival material from 103 colorectal carcinomas, 26 adenomas and 20
samples of normal epithelia.
Results: The number of apoptotic cells was higher in CRCs (1.09 ± 0.13) than in adenomas (0.38 ± 0.23, p = 0.059)
and normal epithelium (0.06 ± 0.04, p = 0.001). In addition, the apoptotic index (AI) was greater in metastatic disease
(stage IV) than in other stages (p = 0.017). No relationship was found between apoptotic rates and age, gender or
tumour grade. However, patients with tumours that showed higher AI values had a significantly lower disease-free
survival (DFS) and overall survival (OS) than those with tumours that had lower AIs (p = 0.020 and p = 0.027). In a
multivariate Cox proportional hazards model, AI remained a significant independent predictor of survival.
Conclusions: We conclude that disregulated apoptosis is an important event during CRC development and
progression. Higher AIs are associated with more aggressive tumours and a poorer prognosis for patients with CRC.
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Currently, colorectal cancer (CRC) represents an im-
portant public health problem due to its high incidence
and mortality. It is the third-most-common tumour type,
and approximately one million new cases of CRC are di-
agnosed per year worldwide [1]. The CRC survival rates
are primarily determined by the stage of the tumour at
diagnosis, as determined by the TNM (Tumour-Node-
Metastases) classification system. At 5 years, 90% of pa-
tients with a localised tumour (a tumour that is confined
to the intestinal wall) will be alive, whereas this percent-
age decreases to 60-70% if the tumour has spread to
regional lymph nodes and is only approximately 5-10%
for cases of CRC that involve metastatic disease. More-
over, approximately 40-50% of the patients that initially
present with early stages of CRC will relapse. Despite* Correspondence: mredondo@hcs.es
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reproduction in any medium, provided the orrecent improvements in CRC management, there remains
a need to find biomarkers that provide prognostic infor-
mation and guide therapy decisions.
Most CRCs progress through a multistep process that
involves a series of genetic alterations; these alterations
produce a phenotypic progression from normal tissue to
adenoma to carcinoma. This tumourigenesis sequence
is proposed by the Vogelstein model and accounts for
approximately 85% of all CRCs [2]. According to this
model, adenomas of the colorectum are precursor lesions
that may undergo malignant transformations and develop
into adenocarcinomas over a period of months or years.
This development involves three physiological phenom-
ena: proliferation, differentiation and cell death. It has
been demonstrated that an increase in proliferative activity
occurs concurrently with the worsening of dysplasia dur-
ing the adenoma-carcinoma transition. However, the role
of apoptosis in this process has not yet been completely
clarified.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients characteristics (n = 103)












Cecum and ascending colon 22 21
Transverse colon 11 11
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pathways: the extrinsic or death receptor-mediated path-
way, which is activated by the binding of specific ligands
(such as FasL, TNF-α and TRAIL) to the receptors of cell
surfaces; and the intrinsic or mitochondrial-mediated
pathway, which is regulated through proteins of the Bcl-2
family and triggered either by the loss of growth factor
signals or in response to genotoxic stress. Therefore the
replication of cells with DNA damage is generally avoided
because harmful genomic alterations typically induce the
activation of apoptosis. It has been widely accepted that
alterations in the physiologic response to DNA damage
can facilitate the accumulation of oncogenic mutations;
this accumulation may eventually lead to the development
of neoplasia.
If the mechanisms that are necessary for maintaining
the balance between proliferation and apoptosis function
properly, then the homeostasis of the colonic epithelium
in the intestinal crypt will be maintained. However, in
this system, which involves a very high cell turnover rate,
the down-regulation of apoptotic function would allow
uncontrolled cell proliferation and tumour development.
In fact, in several studies, a progressive inhibition of
apoptosis during the mutation of cells from normal mu-
cosa to CRC has been demonstrated [3,4]. However,
other studies have suggested a trend towards increased
apoptotic index (AI) during the process of CRC develop-
ment [5-8]. Therefore, further studies are needed to
confirm this trend. In addition, given the emergent evi-
dence indicating the relevance of apoptosis to the patho-
genesis and progression of CRC, the potential prognostic
implications of apoptotic rates have become increasingly
intriguing. Nevertheless, there is a paucity of works dem-
onstrating the prognostic significance of apoptosis in
CRC, and only some researches have reported statistically
significant worse outcomes for patients with higher AIs
[9,10]. In this study, we investigated whether differences
in apoptotic rates could be related to carcinogenesis and
to the survival of CRC, and we report the first evidence
that high AI is associated with a significant decrease not
only in overall survival (OS), but also in disease-free
survival (DFS) among patients with CRC.
Methods
Patients and tissue samples
After excluding patients that had previously been treated
with chemotherapy and/or radiation therapy, a total of
103 CRC from patients who had experienced tumour
resection at the Costa del Sol Hospital between January
2006 and December 2007 were studied. As well 26 sam-
ples belonging to patients with adenomas and 20 normal
colon tissues were studied. Sections of normal colonic
mucosa were obtained from surgical specimens, not
adjacent but remote from carcinoma and considered asnormal by pathologists. All of the tissue samples were
routinely fixed in 10% buffered formalin and embedded
in paraffin blocks. On the other hand, the areas of tu-
mours for the TUNEL assay were selected as well by ex-
pert pathologists, excluding necrotic areas. Table 1 lists
the characteristics of the 103 patients with CRC of this
study. The clinical data were obtained from the tumour
registry and hospital charts of the Costa del Sol Hospital,
and the present study was approved by the Research
Ethics Committee of that hospital. Specimens were
examined from 57 men and 46 women. The mean age of
the patients at surgery was 70 years (range: 45–91). The
follow-up time was calculated to be from the time of the
initial pathologic diagnosis to the last date of contact
with the patient, and the median observation period was
50 months (range: 12–96). The CRCs were characterised
by grade and stage in accordance with the WHO and
TNM classification systems.
In situ localisation of apoptotic cells (TUNEL assay)
To detect apoptotic cells, the in situ labelling of the
3’-ends of the DNA fragments that were generated by
apoptosis-associated endonucleases was performed using
Figure 1 Apoptosis detected by TUNEL assay. Positively stained
cells were very scarce in normal mucosa (A), increased in adenomatous
polyps (B) and especially in adenocarcinomas of the colon
(C). Magnification, 200x (A), 400x (B, C).
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GmbH, Mannheim, Germany). Briefly, deparaffinised
sections were incubated with 20 mg/ml of proteinase K
(Sigma Chemical Co., St. Louis, MO, USA) for 15 minutes.
Following a rinse in PBS, the slides were covered with a
terminal deoxynucleotidyl transferase and nucleotide mix-
ture at a 1:35 dilution for 60 minutes at 37°C. The slides
were then covered with an antifluorescein antibody that
was conjugated with alkaline phosphatase. After the
substrate reaction had occurred, the stained cells were
analysed under a light microscope. The pretreatment of
sections with DNase served as a positive control for the
enzymatic procedures; for a negative control, the same
procedures were performed without the inclusion of the
enzyme. The established morphological features that were
used to identify apoptosis on H&E slides were also used
for TUNEL-stained slides. Cells were defined as apoptotic
if the whole nuclear area of the cell was positively labelled.
Apoptotic bodies were defined as small, positively labelled
globular bodies in the cytoplasm of the tumour cells; these
bodies were found either singly or in groups. In total,
1000 cells were counted for each specimen. The number
of positively stained cells was then divided by 1000 to esti-
mate the percentage of apoptotic cells in each specimen.
We used the median of the apoptotic percentage in our
samples (1%) (range: 0-6%) as a threshold value for sur-
vival studies. The evaluation of the specimens was inde-
pendently performed by two investigators, who had no
access to either the clinical data or the laboratory informa-
tion for the patients of the study.
Statistical analysis
Statistical analyses were performed using the SPSS stat-
istical software program (SPSS Inc., Chicago, IL, USA).
The analysis of the association between apoptosis and
various prognostic factors for CRC used the X2 test for
categorical variables and the analysis of variance test for
continuous variables (which were natural log transformed
if necessary). The relapse-free survival was estimated using
the Kaplan-Meier method, and the survival curves were
compared with the log rank test. Cox’s proportional
hazards survival analysis was used to determine the rela-
tive risk through multivariate analyses. The p <0.05 level




A TUNEL assay was performed to quantify apoptosis
in colon tissue and determine whether the frequency
of apoptosis was related to tumourigenesis. The apop-
totic rate of cells was greater in CRCs (mean 1.09 ± 0.13)
than in adenomas (mean 0.38 ± 0.23, p = 0.059), and the
apoptotic rate was significantly higher in CRCs thanin normal epithelial cells (mean 0.06 ± 0.04, p = 0.001)
(Figure 1). Therefore, apoptosis is related to neoplastic
transformation. With respect to the tumour stage, we
found that the AIs were much greater in metastatic
disease cases (stage IV) than in the localised stages of the
disease (stages I, II and III), with p = 0.017. Apoptotic rates
did not correlate with the gender, age or tumour grade of
patients.
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To determine whether AI correlates with prognosis in
patients with CRCs, we analysed the association between
AI and recurrence-free survival. A significantly lower
DFS was demonstrated by patients with tumours that
had high AIs than by patients with tumours that had
low AIs (p = 0.020). Figure 2 illustrates the Kaplan-Meier
curves for recurrence-free survival, comparing high
versus low AIs. The DFS at 5 years varied depending
on the value of the AI. Thus, for a low AI, DFS at
5 years was 61.8 ± 8.1%, whereas the DFS at 5 years
was 28.5 ± 9.6% for a high AI (AI > 1%), with p =
0.020. To determine the independent prognostic value
of AI, a multivariate analysis was performed using the
Cox proportional hazards model. A high apoptotic
rate was significantly associated with an increased re-
currence rate, and the independent relative risk (RR)
was 2.03 (with a 95% confidence interval (CI) of 1.04-
4.14). As expected, an advanced tumour stage was
also significantly associated with a poor DFS (RR
2.48; the 95% CI was 1.10-5.59). With respect to the
analysis of DFS by stages, we observed that a high AI
was associated with a shorter survival in more advanced
disease (stages III and IV) (p = 0.004) (Figure 3). This
association was not present in earlier stages (data not
shown).Figure 2 The disease-free survival (DFS) of patients, grouped by apop
presenting high AIs (lower line) is significantly shorter than the survival of pOverall survival (OS)
A low AI was associated with a more favourable OS (OS
at 5 years: 74.6 ± 8.8%), whereas a high AI was correlated
with a poor outcome (OS at 5 years: 43.7 ± 11.9%, with
p = 0.027). In a multivariate analysis, we found that AI
and tumour stage were independent prognostic factors
for OS, with RR values of 2.18 (with a 95% CI of 1.08-
4.37) and 2.41 (with a 95% CI of 1.20-4.85), respectively.
Discussion
Normal tissue homeostasis is maintained by a balance
between the proliferation and apoptosis of colonic epi-
thelial cells. These activities are specifically localised
within the intestinal crypt. In normal mucosa, predom-
inantly proliferative activities are found at the lower
part of the crypt, where stem cells reside and split
into daughter cells; by contrast, greater apoptotic fre-
quencies are localised to the top of the crypt because
daughter cells proliferate and differentiate during their
migration up and are shed into the lumen or elimi-
nated by apoptosis upon reaching the top of the crypt
[11]. These gradients are reversed in adenomas, which
feature increased proliferation towards the upper part
of the crypt and more elevated levels of apoptosis at the
bottom of the crypt; a greater overall rate of apoptosis is
found in adenomas than in normal crypts [4,6,12]. Bytotic cell rates. The survival of patients with primary tumours
atients presenting tumours with low AIs (upper line).
Figure 3 The disease-free survival (DFS) of patients with advanced-stage tumours (stages III and IV), grouped by apoptotic cell rates.
Patients with high AIs (lower line) present shorter survival durations than patients with low AIs (upper line).
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omas [6]. An explanation for these distribution patterns is
provided by the role of programmed cell death in the con-
trol of genetic damage. The withdrawal of cells with DNA
mutations through apoptosis, prevents the replication and
expansion of these cells. This protective function explains
why higher AIs may be found in tumours than in normal
tissue, as these elevated AIs may indicate physiological
attempts to eliminate the genetic alterations that are
frequently found in neoplastic cells. It is true that tumour
cells are able to develop mechanisms to evade apoptosis
and become immortal. However, if only the neoplastic
cells with mutations that inhibit apoptosis will survive and
continue proliferating, then apoptosis serves to select the
most aggressive cell specimens for tumour formation.
In addition to genetic damage, other factors, such as
nutrient, growth factor or oxygen deficiencies, can also
stimulate programmed cell death. Indeed, hypoxia is a
common feature of most solid tumours because neopla-
sias that are undergoing rapid proliferation often over-
whelm the capability of existing vessels to provide oxygen.
Malignant cells need to adapt to their microenvironment,
and this confers a more resistant phenotype to these cells,
thereby increasing the risk of tumour progression [4,13].
Another link between cell death and carcinogenesis
has been suggested. It has been observed that apoptotic
cells can have an effect on the tumour microenvironmentand the inmune response in the associated stroma, leading
to an activation of neoplastic progression [14]. Caspase 3,
a marker for apoptosis, has been proposed as the key
signal of dying tumour cells to stimulate the growth or
surviving cells after radiotherapy [15].
Thus, proliferation and apoptosis are coupled. How-
ever, although it is established knowledge that cell prolif-
eration gradually increases with tumour progression,
studies trying to clarify whether the same phenomenon
occurs for apoptosis have produced dissenting results. It
has been argued that these discrepancies could be related
to lack of uniformity in the selection and preparation
of tissue, influencing pre-analytical variables, espe-
cially cold ischemic time and formalin fixation process
[16]. Additionally, differences among the methods that are
used for the detection of apoptosis could influence the
data that are obtained in these studies. Nevertheless,
regardless of the apoptotic detection method that is
chosen, most authors have demonstrated an increase
in the AIs that are observed during the course of the
progression from normal mucosa to adenoma to car-
cinoma and a good correlation has been found when
different methods have been compared, like M30 anti-
body or cleaved caspase 3 [5-8,17].
Moreover, the primary article that reported a progressive
decrease in AIs from normal mucosa to carcinoma [3] in-
corporates certain important methodological limitations,
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confirm that apoptosis upregulation is implicated in the
colorectal carcinogenesis process that transforms normal
tissue to premalignant and malignant lesions.
This progressive increase in apoptotic rate during the
course of tumour development has been observed not
only in CRC but also in other cancer types. For example,
the AIs are greater in lymph node metastases than in
primary breast carcinomas [18], and AIs are also positively
correlated with the pathologic grades of gliomas [19]. AI
elevation has also been observed in the carcinogenesis of
the endometrium [20] or the lung [21]; according to the
observations of Törmänen et al., the demonstrated AI in
these contexts also increased with the severity of the dys-
plasias that were observed. In experiments with neoplastic
stomach samples, less apoptosis was present in the early
stages of gastric cancers than in advanced stages of these
cancers, an observation that has been addressed by several
different authors [22,23].
Once we have demonstrated the participation of apop-
tosis in carcinogenesis, the next logical step is to test
its association with patient prognoses. These tests have
been conducted both in CRC and in non-colorectal neo-
plasms [24,25]. The existing studies that have attempted
to address the prognostic significance of AI in CRC have
produced inconclusive results. Several investigations have
demonstrated that reduced apoptosis is associated with
adverse outcomes and metastatic stages, some of them
only in case of distal colon carcinomas [26], but more
recent studies have suggested an inverse relationship be-
tween AI and survival [9,10,27]. Because proliferation and
apoptosis are closely related, it would not be unusual to
discover that compared with tumours that develop over
a more indolent course, more aggressive tumours are
more proliferative and present higher AIs. In fact, both
Watanabe et al. [28] and Evertsson et al. [29] observed an
increase in apoptosis and proliferation activities during
the course of tumour progression from early to advanced
stages of CRC. The same conclusion was reached in a
study of rectal cancer by Kim et al. [30]; these researchers
also linked apoptosis to lymphatic invasion. Recently,
authors that were investigating the relationship between
KRAS mutations and prognoses for CRC cases have
observed that KRAS mutations lead to the higher
turnover of colorectal tumour cells, which stimulates
both mitosis and apoptosis and is related to a poor
survival of CRC [31].
Other markers have been used to study the relation-
ship between apoptosis and survival. Thus, the prognos-
tic significance of cleaved caspase 3 has been evaluated
with varying conflicting results [14,32,33]. Alternatively,
when apoptosis was measured by M30 antibody, an
association between elevated AI and reduced survival
was observed [34,35].In the present study, we report that a high AI is signifi-
cantly associated with both decreased DFS and reduced
OS among patients with invasive CRC. To our knowledge,
this is the first time that these data are reported. As we
expected, the AI was higher in the more advanced stages
of the illness, a result that is in accordance with previously
published findings [29,36]. Thus, apoptotic rates increase
as tumours progress. Moreover, in advanced disease
stages, a high AI is associated with a shorter DFS duration.
Therefore, the determination of AI in stages III and IV
may help to identify patients who might expect a worse
outcome and would therefore most likely benefit from
more intense regimens of chemotherapy.
In summary, our study demonstrates an increase in
apoptosis during colorectal carcinogenesis and a distinct
correlation between apoptotic rates and survival out-
comes. At the present time, the importance of apoptosis
and antiapoptotic signalling pathways in the pathogenesis
and prognosis of CRC is being increasingly recognised.
Molecules involved in these pathways represent potential
diagnostic markers and therapeutic targets and are there-
fore the focus of numerous research efforts.
Conclusions
We conclude that disregulated apoptosis is an important
event during CRC development and progression. Our
study demonstrates an increase in apoptosis during colo-
rectal carcinogenesis and a distinct correlation between
apoptotic rates and survival. Higher AIs are associated with
more aggressive tumours and a poorer prognosis for pa-
tients with CRC. To our knowledge, this is the first study
reporting evidence that high AIs are significantly associ-
ated with both decreased DFS and reduced OS among pa-
tients with invasive CRC. Therefore, AI is an independent
prognostic factor in CRC that could help to guide therapy
decisions, and molecules involved in apoptosis regulation
represent potential diagnostic markers and therapeutic
targets.
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